Proxy Results (Form 8-K)

Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 17, 2026, Cognition Therapeutics, Inc. (the "Company") held its Annual Meeting of Stockholders (the "Annual Meeting"). The Annual Meeting was conducted virtually, and the following is a brief description of the final voting results for each of the proposals submitted to a vote of the stockholders at the Annual Meeting, which are described in detail in the Company's definitive proxy statement for the Annual Meeting, filed with the U.S. Securities and Exchange Commission on April 27, 2026.

Proposal 1 - Election of Class II Directors. Each of Aaron Fletcher, Ph.D., and Lisa Ricciardi were elected to the Board of Directors as Class II directors to serve until the Company's 2029 Annual Meeting of Stockholders and until their successors, if any, are elected or appointed, or their earlier death, resignation, retirement, disqualification or removal as follows:

Proposal 2 - Ratification of Independent Registered Public Accountants. The appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the 2026 fiscal year was ratified, as follows: